Neurotoxin
CGRP monoclonal antibodies (MABs)
Gepants
Natural products and supplements
Post 903 - Should NOT be first line, less frequently used, low evidence for efficacy but may be used in selected cases with significant comorbidity.
Medications should be discussed with healthcare providers before use. Contraindications vary and may include specific medical conditions or potential interactions. For detailed guidelines and further information on managing migraines with these medications, refer to the referenced studies and resources.
References
- Pringsheim T, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2)
- Rajapakse T, Pringsheim T. Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. Headache. 2016;56(4):808-16.
- Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018;58 Suppl 3:238-75.
- QULIPTA prescribing information (https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/QULIPTA_PM_EN.pdf)
- Argyriou AA, et al. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. Expert Rev Neurother. 2022;22(6):469-88.
Post #903
